Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL)
Dr. Nallathamby presented on his abiotic biomimicking antibacterial Nanoparticles, and how they were successfully tested against A. baumannii BA1605 S.aureus USA300, P.aeruginosa FRD1, K. pneumoniae, C.striatum, E. faecalis, and S. pyogenes. We saw little to no evolution of resistance at doses above the MIC. Additionally, we observed what looks like inflammation-free wound healing in mouse and rat models. The wound size stabilizes as soon as the formulation is …
Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa
Congratulations to REUs Argerie Guevara (NURF’21), and Kevin Armknecht (NURF’23) and Carlie Kudary (#BIPH) on the prolonged antibacterial action formulation of standard antibiotics to tackle MRSA and P.aeruginosa. More to come this year. #AMR #GOIRISH https://doi.org/10.1093/milmed/usae079
NIH Funding Opportunities
- Notice of Special Interest (NOSI): Research on rare cancers across the cancer control continuum December 30, 2024Notice NOT-CA-25-010 from the NIH Guide for Grants and Contracts
- Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Clinical Trial Not Allowed) December 30, 2024Funding Opportunity RFA-DA-25-074 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites grant applications aimed at elucidating neuroimmune and neuronal-glial pathophysiological mechanisms of HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the presence of addictive substances. Specific emphasis is […]
- Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) December 30, 2024Funding Opportunity PAR-25-056 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research […]
- Notice Announcing the National Institute of Mental Health (NIMH) Expectations for Collection of Common Data Elements December 30, 2024Notice NOT-MH-25-055 from the NIH Guide for Grants and Contracts
- Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) December 30, 2024Funding Opportunity PAR-25-362 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or […]
- Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) December 30, 2024Funding Opportunity PAR-25-332 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published […]
- Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) December 30, 2024Funding Opportunity PAR-25-331 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for […]
- Notice of NIBIB Participation in RFA-EY-25-001: "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)" December 30, 2024Notice NOT-EB-24-021 from the NIH Guide for Grants and Contracts
- Notice of Participation of the National Institute on Aging in RFA-NR-25-003, "Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional)" December 30, 2024Notice NOT-AG-24-094 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Research to Identify State and Local Policies, Programs, and Strategies that have Contributed to Reductions in Overdose Deaths December 30, 2024Notice NOT-DA-24-057 from the NIH Guide for Grants and Contracts
Recent Comments